These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36032790)

  • 1. Standardisation and international adoption of defined approaches for skin sensitisation.
    Casati S; Asturiol D; Browne P; Kleinstreuer N; Régimbald-Krnel M; Therriault P
    Front Toxicol; 2022; 4():943152. PubMed ID: 36032790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods.
    Casati S; Aschberger K; Barroso J; Casey W; Delgado I; Kim TS; Kleinstreuer N; Kojima H; Lee JK; Lowit A; Park HK; Régimbald-Krnel MJ; Strickland J; Whelan M; Yang Y; Zuang V
    Arch Toxicol; 2018 Feb; 92(2):611-617. PubMed ID: 29127450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to resolve inconclusive predictions from defined approaches for skin sensitisation in OECD Guideline No. 497.
    Macmillan DS; Chilton ML; Gao Y; Kern PS; Schneider SN
    Regul Toxicol Pharmacol; 2022 Nov; 135():105248. PubMed ID: 36007801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OECD harmonised template 201: Structuring and reporting mechanistic information to foster the integration of new approach methodologies for hazard and risk assessment of chemicals.
    Carnesecchi E; Langezaal I; Browne P; Batista-Leite S; Campia I; Coecke S; Dagallier B; Deceuninck P; Dorne JLC; Tarazona JV; Le Goff F; Leinala E; Morath S; Munn S; Richardson J; Paini A; Wittwehr C
    Regul Toxicol Pharmacol; 2023 Aug; 142():105426. PubMed ID: 37277057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency classification of isothiazolinone compounds based on defined approaches of skin sensitization in OECD GL 497.
    Kim H; Park J; Lee H; Son J; Park Y; Bae H; Park SY; Lee SH; Seo J; Shin S; Park K
    Environ Anal Health Toxicol; 2023 Dec; 38(4):e2023026-0. PubMed ID: 38298045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients.
    Gilmour N; Kern PS; Alépée N; Boislève F; Bury D; Clouet E; Hirota M; Hoffmann S; Kühnl J; Lalko JF; Mewes K; Miyazawa M; Nishida H; Osmani A; Petersohn D; Sekine S; van Vliet E; Klaric M
    Regul Toxicol Pharmacol; 2020 Oct; 116():104721. PubMed ID: 32645429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying a next generation risk assessment framework for skin sensitisation to inconsistent new approach methodology information.
    Gilmour N; Alépée N; Hoffmann S; Kern PS; Van Vliet E; Bury D; Miyazawa M; Nishida H; Cosmetics Europe
    ALTEX; 2023; 40(3):439-451. PubMed ID: 36919358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacing the refinement for skin sensitization testing: Considerations to the implementation of adverse outcome pathway (AOP)-based defined approaches (DA) in OECD guidelines.
    Kolle SN; Landsiedel R; Natsch A
    Regul Toxicol Pharmacol; 2020 Aug; 115():104713. PubMed ID: 32562760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Defined Approaches for Skin Sensitization to Agrochemical Products.
    Strickland J; Truax J; Corvaro M; Settivari R; Henriquez J; McFadden J; Gulledge T; Johnson V; Gehen S; Germolec D; Allen DG; Kleinstreuer N
    Front Toxicol; 2022; 4():852856. PubMed ID: 35586187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adverse outcome pathway concept: A basis for developing regulatory decision-making tools.
    Delrue N; Sachana M; Sakuratani Y; Gourmelon A; Leinala E; Diderich R
    Altern Lab Anim; 2016 Oct; 44(5):417-429. PubMed ID: 27805824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of a defined approach based on a stacking prediction model to identify skin sensitization hazard.
    Tourneix F; Alépée N; Detroyer A; Eilstein J; Martinozzi Teissier S; Nardelli L; Noçairi H; Pauloin T; Piroird C; Del Bufalo A
    Toxicol In Vitro; 2019 Oct; 60():134-143. PubMed ID: 31100378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adverse outcome pathway for skin sensitisation: Moving closer to replacing animal testing.
    Schultz TW; Dimitrova G; Dimitrov S; Mekenyan OG
    Altern Lab Anim; 2016 Oct; 44(5):453-460. PubMed ID: 27805828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of peptide reactivity assays for skin sensitisation hazard identification and risk assessment.
    Gerberick GF
    Altern Lab Anim; 2016 Oct; 44(5):437-442. PubMed ID: 27805826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying the skin sensitisation adverse outcome pathway (AOP) to quantitative risk assessment.
    Maxwell G; MacKay C; Cubberley R; Davies M; Gellatly N; Glavin S; Gouin T; Jacquoilleot S; Moore C; Pendlington R; Saib O; Sheffield D; Stark R; Summerfield V
    Toxicol In Vitro; 2014 Feb; 28(1):8-12. PubMed ID: 24184331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus of classification trees for skin sensitisation hazard prediction.
    Asturiol D; Casati S; Worth A
    Toxicol In Vitro; 2016 Oct; 36():197-209. PubMed ID: 27458072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Devising a Tier-based Skin Sensitisation Screening Strategy for Personal Care and Cosmetic Products.
    Fung ES; Towle KM; Monnot AD
    Altern Lab Anim; 2020 Mar; 48(2):70-77. PubMed ID: 32441989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A defined approach for predicting skin sensitisation hazard and potency based on the guided integration of in silico, in chemico and in vitro data using exclusion criteria.
    Macmillan DS; Chilton ML
    Regul Toxicol Pharmacol; 2019 Feb; 101():35-47. PubMed ID: 30439387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternatives for skin sensitisation: Hazard identification and potency categorisation: Report from an EPAA/CEFIC LRI/Cosmetics Europe cross sector workshop, ECHA Helsinki, April 23rd and 24th 2015.
    Basketter D; Ashikaga T; Casati S; Hubesch B; Jaworska J; de Knecht J; Landsiedel R; Manou I; Mehling A; Petersohn D; Rorije E; Rossi LH; Steiling W; Teissier S; Worth A
    Regul Toxicol Pharmacol; 2015 Nov; 73(2):660-6. PubMed ID: 26456663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward a Better Testing Paradigm for Developmental Neurotoxicity: OECD Efforts and Regulatory Considerations.
    Sachana M; Shafer TJ; Terron A
    Biology (Basel); 2021 Jan; 10(2):. PubMed ID: 33498772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.